Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Johnson and Johnson announces drug safety

Johnson and Johnson announces drug safety

20th March 2006

Clinical trials have revealed that the use of paracetamol by patients with chronic liver disease is safe as along as used as directed.

McNeil Consumer and Speciality Pharmaceuticals, a division of McNeil-PPC and a member of the Johnson & Johnson family of companies, said that there is no evidence that therapeutic use of paracetamol aggravates liver disease.

“The results of this review refute the popular misconception that liver disease patients should avoid using [paracetamol] to manage their pain,” said Dr Gordon Benson of the Department of Medicine at the University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School.

The American Journal of Therapeutics revealed the findings through further study of data generated when patients with chronic liver disease were treated with the drug.

After 13 days of treatment with the maximum recommended dose of paracetamol, 20 patients with stable chronic liver disease were found to have no evidence of toxicity generated by the drug.

track© Adfero Ltd

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.